What Actually Works Now: Hair Loss Treatment in 2026
I started behind a chair in 1999 and stood behind one until 2022. Over those years I watched a great deal of hair loss walk through the door, and I watched what the industry told those people to do about it.
For most of that time, the advice barely moved. The same two drugs, the same devices, the same supplements, the same shrug for anything autoimmune. Then in the last few years it moved a lot — and most of what is written online about hair loss still describes the older world.
So this is the update. What has genuinely changed, what has not, and what is being sold as change but isn't here yet.
I am a hairdresser, not a doctor, and nothing here is a recommendation to take anything. Everything below is prescription territory and belongs in a conversation with a physician. What I can do is tell you what exists now, so you walk into that conversation knowing what to ask about.
First, what has not changed
The cycle. Anagen, catagen, telogen, and the three-month delay between a cause and its consequence. That was correct in 1999 and it is correct now, and it is still the thing most people misunderstand.
And the two foundations of pattern hair loss treatment are the same two drugs: topical minoxidil, approved in the late eighties, and oral finasteride, approved in the late nineties. They remain the base of treatment, and the reason is not inertia — it is that they now carry more than thirty years of accumulated safety data between them, which nothing newer can match.
That is worth sitting with. For three decades, the entire field added no new mechanism at all.
The real breakthrough happened somewhere else
Alopecia areata — the autoimmune kind, the sudden well-defined bald patches — is where medicine actually moved, and it moved dramatically.
For most of my career, the options for severe alopecia areata amounted to steroids, immunosuppressants, and hope. For the most severe forms, where all scalp hair or all body hair is lost, the honest prognosis was poor and the advice was to manage expectations. I had that conversation with clients more than once and there was nothing useful to offer at the end of it.
Since 2022 the FDA has approved three drugs from a class called JAK inhibitors specifically for severe alopecia areata: baricitinib in 2022, ritlecitinib in 2023, and deuruxolitinib in 2024. The first of these was the first oral drug ever approved for the disease. They are now considered first-line treatment for severe cases, including the total and universal forms that were once treated as near-hopeless.
The results are real without being miraculous. Across the pivotal trials, roughly a third to 40% of patients with extensive loss reached substantial regrowth — meaning most of the scalp covered — after around eight or nine months. Longer follow-up shows regrowth continuing over time, and some people respond late rather than not at all.
These are serious immune-modulating drugs and they carry serious considerations: infection risk and clotting concerns among them, with monitoring required throughout. This is not a decision anyone should make from a website. But the existence of a genuine, approved, effective option for a condition that had none is the single largest change in this field in my working lifetime.
One practical note that matters for cost: an older drug in the same family, tofacitinib, went generic in the US in 2026 and is now available at a fraction of the previous price. It is used off-label for this, and it is worth asking a dermatologist about if the approved options are out of reach financially.
Pattern loss: the quiet shift
For ordinary pattern thinning, the notable change is not a new drug but a new route for an old one.
Minoxidil, the same molecule that has been in bottles since the eighties, is increasingly prescribed as a low-dose tablet rather than a topical solution. This is off-label — the tablet was originally a blood pressure medication — but the practice has grown substantially and the evidence base has grown with it.
What the research shows is roughly comparable results to the topical version, with better adherence, lower cost, and none of the greasy scalp and daily application that makes so many people quit. A head-to-head randomised trial found the oral version did not beat the topical one over six months — so this is a convenience and adherence story, not a potency story. Anyone selling it as a breakthrough is overselling.
It has real side effects. Hair growth in places you did not ask for it is the most common by a distance, affecting around a quarter of users. Transient shedding in the early weeks is common enough that people quit before it works. Mild fluid retention happens. It is contraindicated in pregnancy and in several cardiac situations, and the dose is set by a physician after assessing you — which is exactly why I am not naming numbers here.
What is coming, and is not here
You will start seeing a drug called clascoterone written about as though you can buy it. You cannot.
It is genuinely interesting: a topical that blocks the androgen receptor in the scalp directly, rather than lowering hormones throughout the body the way finasteride does. That makes it the first new mechanism for pattern hair loss in over thirty years, which is why it gets the coverage it does.
The trial programme is substantial — around 1,465 men across two identical phase 3 trials at 51 sites in the US and Europe, both hitting their primary endpoint, with twelve-month data reported in spring 2026 showing continued gains for those who stayed on it.
But regulatory filings were still ahead as of mid-2026, with submissions expected in 2027 and realistic availability some time after that. On raw regrowth numbers it appears to deliver somewhat less than finasteride; its argument is a cleaner side effect profile, particularly for men who cannot tolerate systemic treatment.
So: promising, well-evidenced, and years away. If a clinic offers it to you today, ask what they are actually selling you.
A related warning worth passing on: the FDA has raised concerns about compounded topical finasteride, including the risk of inadvertent exposure to pregnant women in the household. Compounded is not the same as approved.
What quietly got retired
Two pieces of advice were common in salons and clinics for years, and both are worth correcting rather than updating, because neither was ever sound.
Hair mineral analysis as a nutritional diagnostic. The pitch is that you send a hair sample to a lab and it tells you which minerals you are short of. The evidence does not support this. The methods are legitimate in forensic and occupational toxicology, but for assessing whether your zinc or iron is low, the results are confounded by shampoo residue, tap water, and hair treatments, and different commercial labs interpret the same sample differently because they use different reference ranges. If you want to know your iron status, the test for that is a blood test.
Megadose vitamins as a treatment. The old salon advice routinely included daily vitamin A at a level at or above the adult upper limit. Chronic excess vitamin A causes hair loss. That is not a small error — it is a recommendation that can produce the problem it is meant to solve. The same logic applies to sustained high-dose zinc, which interferes with copper.
The general principle is one I keep coming back to: correcting a deficiency helps, and exceeding a sufficiency does nothing good and sometimes does harm.
What I would actually do
Find out what you have before you treat it. Diffuse shedding, pattern thinning, patchy autoimmune loss and breakage are four different problems, and the treatments do not transfer between them. Start with Shedding vs. Breakage and Why It Started Three Months Ago, both free.
Get the basic bloodwork. The short list of tests worth asking for by name is in Scalp Care.
Then see a dermatologist rather than a website — including this one. Everything genuinely effective on this page requires a prescription and a physician who has looked at your scalp.
And start one thing at a time. If you begin four treatments in one month and something improves, you have learned nothing about which one to keep paying for.
As an Amazon Associate I earn from qualifying purchases. I sell hairbrushes; I do not sell any treatment described on this page and could not if I wanted to. Nothing here is medical advice, and every drug named requires a prescription and a doctor.
The one thing on this page I sell
Everything named above needs a prescription and a doctor. Low-level laser therapy does not, and it is the only treatment discussed here that I have any commercial interest in. I use one on my own head. What it is, how the protocol changed, and which of the three sizes to buy.
If you are also considering a supplement, read the biotin section on the scalp page before you start one. High-dose biotin skews blood tests, including the one used to diagnose a heart attack.